Cytokinetics Inc (NAS:CYTK)
$ 48.98 -10.25 (-17.31%) Market Cap: 5.14 Bil Enterprise Value: 6.35 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc FDA Advisory Committee for Omecamtiv Mecarbill Update Call Transcript

Dec 14, 2022 / 01:30PM GMT
Release Date Price: $41.41 (+8.04%)
Operator

Good morning, and welcome, ladies and gentlemen, to Cytokinetics conference call to discuss the outcome of yesterday's FDA Advisory Committee Meeting for omecamtiv mecarbil. At this time, I would like to inform you that this call is being recorded (Operator Instructions)

I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser
Cytokinetics, Incorporated - SVP

Good morning, and thanks for joining us on the call today. On the call with me today are Robert Blum, President and Chief Executive Officer, who will provide a summary of the Advisory Committee outcome and implications for the potential approval of omecamtiv mecarbil; as well as Fady Malik, EVP of Research and Development; Andrew Callos, EVP and Chief Commercial Officer; and Ching Jaw, SVP and Chief Financial Officer, who will all participate in our Q&A.

Please note that portions of the following discussion including our responses to questions, contains statements that relate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot